Drugs / N-Rephasin® SAL200
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03446053 | Feb 2018 → Feb 2019 | methicillin-resistant staphylococcus aureus infectious disease, methicillin-susceptible staphylococcus aureus infectious disease | Intron Biotechnology, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03089697 | Mar 2017 → Nov 2019 | staphylococcus aureus infection | Intron Biotechnology, Inc. | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | N-Rephasin SAL200 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03089697 ↗ |
| Known as | SAL-1 | “A single dose of SAL200 (SAL-1, 3mg/kg) intravenous administration of the study drug, in addition to the conventional standard treatment (antibiotics) for MRSA/MSSA” NCT03089697 ↗ |
| Route | Intravenous | “a single intravenous dose of the N-Rephasin® SAL200 (3 mg/kg)” NCT03089697 ↗ |